Abstract 246P
Background
Despite various awareness programmes and strict regulations for consumption of tobacco and alcohol, the incidence of oral cavity cancer is increasing in low and middle income countries. We have reported here clinico-epidemiological profile of 343 oral cavity cancer patients. Although, treatment guidelines exist, treatment failure is seen in more than 50% of patients.
Methods
We retrospectively analysed the data of 343 oral cavity cancer patients who reported to our department during 2010-2015. Detailed history and clinical examination followed by requisite investigations were done and treatment was given as per the existent guidelines.
Results
Out of 343 patients, 283 (82.5%) were males while 60 (17.4%) were females with a male: female ratio of 4.7:1. The mean and median age for the cohort was 46.2 yrs and 45 yrs, respectively. More patients presented in the age group of 31-40 yrs (29.4%) and 41-50 yrs (27.4%). The youngest patient was 21 yrs while the oldest was 85 yrs. Tongue was the most common site of involvement followed by buccal mucosa. Histopathologically, tumours with moderate differentiation were most frequent followed by well differentiated. Approximately, 60% patients underwent surgery with or without adjuvant radiation. Remaining 40% cases, for whom surgery could not be done, received definitive radiation. Overall, however, 40% of cases had treatment failure despite aggressive multimodality treatment with local recurrence observed in more than half. Locoregional recurrence occurred in 19.1% while disease metastasized to distant areas in 8.8% cases.
Conclusions
Our study provided a clinico-epidemiological profile and failure rates of patients having oral cavity cancers in North India. We have tried to study various risk factors associated with the disease. Significant number of patients presents very late in our setting and so failure rates are unacceptably high. Hence, there is a need to study various therapies for effective management without adding any significant financial burden on patients.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
140P - Lenvatinib + everolimus in mRCC that has progressed on immunotherapy: A real-world single center experience
Presenter: CHINNU JOMI
Session: Poster viewing 03
141P - Real-world study of cabozantinib treatment of advanced renal cell carcinoma in Taiwan
Presenter: Yu-Chieh Tsai
Session: Poster viewing 03
143P - Clinical outcomes of systemic therapy for hemodialysis patients with metastatic renal cell carcinoma
Presenter: Shun Iwasa
Session: Poster viewing 03
144P - Association between immune-related adverse events and survival in metastatic renal cell carcinoma treated with nivolumab plus ipilimumab
Presenter: Takanori Hayase
Session: Poster viewing 03
145P - Treatment outcomes and FGFR alterations in unresectable locally advanced or metastatic urothelial cancer in Taiwan
Presenter: Jian-Ri Li
Session: Poster viewing 03
146P - Comparison of the survival outcomes between primary and secondary muscle-invasive bladder cancer: A propensity score-matched Chinese cohort
Presenter: WAICHAN LOK
Session: Poster viewing 03
Resources:
Abstract
147P - Activity of single-agent PD-1/PD-L1 inhibitors in 1st-line (1L) “platinum-ineligible” patients (pts) with metastatic urothelial cancer (mUC) in real-life clinical practice
Presenter: Javier Molina Cerrillo
Session: Poster viewing 03
149P - A need for clear definitions and improved management for BCG-unresponsive tumors in Asia-Pacific
Presenter: Lui Shiong Lee
Session: Poster viewing 03
Resources:
Abstract